PerkinElmer, Millipore, JPT Peptide Technologies, University of Edinburgh, Sigma-Aldrich, Beckman Coulter, Lumigen, NCI, University of Puerto Rico | GenomeWeb
PerkinElmer CEO Cites Cell Screening Technologies as ‘Acquisition Priorities’
 
Recognizing the recent increased uptake of cell-based assays in drug discovery, a high-ranking PerkinElmer official last week said the company has made cellular screening technologies and related consumables and reagents “acquisition priorities,” and that it will continue to build out its cell-based screening platforms, particularly in the areas of GPCRs and kinases.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.